Object

The Medical Innovation Program (MIP) for Human Reproduction is an initiative by Merck, Darmstadt, Germany that supports early stage innovation in the field of Human Reproduction. The goal of MIP is to translate biomedical science into clinical applications for the benefit of patients by providing funding and support throughout the translation process.

The MIP is an ecosystem of collaboration, a "Collaborative Network" that connects participants and their research teams with a range of innovative services and experts.

Main features

MIP funding operates in three phases based on the stage of your project. The three phases are:

- Conception Phase: Develop a concrete business plan in 3 months with key milestones which will be used to track performance.

- Incubation Phase: Achieve proof of principle and develop prototype. Key Performance Indicators (KPIs) will be used to measure the success of the project.

- Development Phase: Budget will be agreed on a case by case basis to develop a marketable product. Milestones and KPIs will be used to track and grade the success of the project.

Documentation

- Project summary

- Team details (leader, group members and competency, affiliation etc.)

- Survey of the field and opportunity (medical need/market considerations)

- Development plan:

- Short-term and long-term development steps

- Significance

- Innovation

- Approach

- Milestones and timelines

- IP considerations

- Budget and justification (incl. costs breakdown)

- Assurances

- Resources

Deadline

The program operates without formal deadlines and applications are being accepted on a rolling basis.

In case of interest, please contact with Research Management Department.